Skip to main content
HR 7640 117th Congress House Health

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Introduced: May 3, 2022 Introduced by: Bilirakis, Gus M. Republican · Florida See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 3, 2022
Referred to the House Committee on Energy and Commerce.
May 3, 2022
Introduced in House
 Plain-English summary Congressional Research Service

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

What's happening now May 3, 2022

Referred to the House Committee on Energy and Commerce.

 Committees of jurisdiction 1